Equities
  • Price (USD)1.25
  • Today's Change-0.029 / -2.26%
  • Shares traded200.00
  • 1 Year change--
  • Beta0.6860
Data delayed at least 15 minutes, as of May 17 2024 16:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cyberdyne Inc is engaged in the research, development, manufacture, sale, and maintenance management related to Cybernics technology. The Company mainly uses human and the Internet of Things (IoH/IoT), robots, and artificial intelligence (AI) Cybernics technology to develop Cybernic systems. It develops the Cybernics treatment service business and the training service business that utilize Cybernics technology. The Company develops in various fields centered on HAL. HAL is a robot treatment device for the purpose of improving and regenerating the physical function of patients, a welfare device and life support device for the purpose of supporting independence, and a work support equipment. It can be used for various purposes by being worn and used by people. The Company is also involved in the productization of AI-equipped transport robots; cleaning robots; Cyin, which is used for communication with people with disabilities, and electrocardiography devices.

  • Revenue in USD (TTM)26.55m
  • Net income in USD-8.47m
  • Incorporated2004
  • Employees257.00
  • Location
    Cyberdyne Inc2-2-1, Gakuen-MinamiTSUKUBA-SHI 305-0818JapanJPN
  • Phone+81 298553189
  • Fax+81 298553181
  • Websitehttps://www.cyberdyne.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
InfuSystem Holdings Inc127.41m84.00k137.14m499.002,316.552.6211.161.080.00280.00285.912.461.2310.666.57255,330.700.08114.600.09555.6950.2756.430.06594.071.511.560.36410.0014.4413.384,744.44--6.01--
Akoya Biosciences Inc93.57m-68.01m140.62m330.00--4.30--1.50-1.47-1.471.990.66320.60562.207.08283,554.50-44.01---56.06--55.99---72.68--2.38-10.150.7013--29.09--10.36------
Electromed Inc53.50m4.36m141.78m170.0033.143.3327.392.650.49420.49426.084.921.173.312.25314,682.309.497.8611.039.1476.4176.258.147.385.87--0.000.0015.3811.1737.3511.0024.58--
TELA Bio Inc63.15m-40.30m154.83m227.00--10.76--2.45-1.67-1.672.610.58340.96681.377.60278,180.60-61.70-52.00-79.77-60.9568.9765.32-63.82-107.653.23-8.520.7387--41.1347.85-5.35---17.12--
Accuray Inc430.55m-21.49m161.77m1.02k--3.94--0.3757-0.2197-0.21974.420.41390.91781.865.72420,462.90-4.58-1.45-7.84-2.4833.0637.86-4.99-1.620.778-0.38570.8086--4.122.03-73.56--13.92--
Semler Scientific Inc65.88m21.69m162.58m92.008.282.047.282.472.782.788.4511.260.85515.138.51716,097.8028.1438.8331.1444.4189.4390.2232.9232.5812.11--0.00--20.2825.9843.6932.64-0.3821--
Clearpoint Neuro Inc26.16m-20.63m170.01m107.00--4.92--6.50-0.8326-0.83261.051.260.50371.2610.08244,495.30-39.71-34.75-49.90-39.6757.1064.75-78.84-76.912.61--0.2237--16.5626.64-34.40--75.30--
Stereotaxis Inc27.10m-21.22m172.47m122.00--11.84--6.36-0.2575-0.25750.32880.24390.60121.456.14222,155.70-44.08-25.02-63.05-34.1255.1667.57-73.32-41.901.79--0.00---4.89-1.82-12.33--6.63--
Cyberdyne Inc - ADR26.55m-8.47m172.49m257.00--0.9977--6.50-0.04-0.040.12541.250.08141.949.04103,319.70-2.90---2.95--49.60---35.62--17.29--0.015--52.98--40.16------
CVRx Inc42.09m-52.01m179.03m200.00--2.70--4.25-2.48-2.482.013.070.36780.67815.64210,430.00-45.45---48.95--84.45---123.58--10.87-21.110.3064--74.89--0.5528------
Orchestra Biomed Holdings Inc2.22m-51.64m186.45m56.00--3.26--84.14-1.47-1.470.0631.600.02031.0130.9939,571.43-47.18---52.58--92.06---2,330.46--7.33--0.00---21.88---37.91------
Outset Medical Inc125.08m-168.77m186.64m480.00--2.00--1.49-3.38-3.382.501.800.35291.823.53260,577.10-47.61-41.40-54.98-47.2924.615.71-134.93-159.055.32-32.130.6786--13.00130.43-6.04--14.27--
Inogen Inc321.52m-96.68m208.19m834.00--1.08--0.6475-4.15-4.1513.818.150.9176.036.83385,519.20-27.57-8.23-34.28-9.5340.5444.54-30.07-10.312.36--0.00---16.32-2.49-22.30--26.34--
Delcath Systems Inc4.61m-49.79m210.33m76.00--13.17--45.65-2.65-2.650.23570.57470.13820.45454.5660,618.42-149.30-116.57-249.28-243.2170.5471.02-1,080.73-1,235.372.25-42.250.3348---24.05-9.53-30.60---5.26--
Butterfly Network Inc68.08m-121.92m217.03m225.00--1.06--3.19-0.5893-0.58930.3290.96850.20450.69544.97302,577.80-36.61---42.07--26.50---179.08--3.34--0.00---10.21--20.76------
Neuropace Inc69.07m-31.51m235.04m171.00--16.36--3.40-1.18-1.182.590.49940.67351.626.63403,935.70-30.72---34.60--73.97---45.61--5.56-4.670.8019--43.72--30.00------
Data as of May 17 2024. Currency figures normalised to Cyberdyne Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.